Methods

Study Protocol
The NU-HIT trial for POAF was a randomized, double-blind, placebo-controlled study that enrolled patients undergoing isolated coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB). Patients who had cardiogenic shock, sinus bradycardia (≤50 per minutes at rest), atrioventricular block, hypothyroidism/hyperthyroidism, a history of AF or other arrhythmia, repeat CABG, and off-pump or on-pump beating CABG were excluded. Subjects were randomized preoperatively by the envelope method to the carperitide group receiving infusion of carperitide from initiation of CPB or the placebo group receiving physiological saline. In Japan, carperitide is approved for treating acute cardiac failure, but not for administration during cardiac surgery. Therefore, approval for this study was obtained from the Ethics Committee of Nihon University Itabashi Hospital; the details of the study were explained to the subjects, and informed consent was obtained from each patient. This study was registered with the University Hospital Medical Information Network (study ID: UMIN000003958). Infusion of carperitide or saline was started at 0.02 µg/dL per minute from initiation of CPB. The infusion rate was decreased to 0.01 μg/kg per minute on resuming oral medication, and infusion was discontinued after another 12 hours.
End Points
The primary end point was occurrence of AF ≤1 week postoperatively. Secondary end points were as follows: (1) the early postoperative outcome (operative mortality and complications); (2) plasma renin activity, angiotensin-II, and aldosterone; (3) brain natriuretic peptide (BNP), atrial NP (ANP), and cGMP; (4) creatine kinase MB isoenzyme and human heart fatty acid-binding protein (H-FABP); (5) high-sensitivity C-reactive protein; and (6) the ejection fraction (EF) measured by echocardiography. H-FABP is a low molecular weight soluble protein involved in intracellular transport of free fatty acids, which is specific to the myocardium and has been reported to be useful for detecting acute myocardial infarction earlier than creatine kinase MB isoenzyme. Serum H-FABP was measured by latex coagulating nephelometry.
Continuous electrocardiographic monitoring was done for 1 week postoperatively to detect AF, which was defined as persistence of this arrhythmia for >5 minutes or as AF affecting hemodynamics that required treatment.
Investigation of factors associated with AF: with regard to preoperative factors (aged ≥70 years, male sex, emergency surgery, coronary risk factors [diabetes mellitus, hypertension, dyslipidemia, obesity, and smoking], cerebral infarction, chronic kidney disease [estimated glomerular filtration rate <60 mL/min], hemodialysis, chronic obstructive pulmonary disease, peripheral arterial disease, 
WHAT IS KNOWN
• Postoperative atrial fibrillation often occurs early after surgery, and it influences long-term mortality.
• Postoperative atrial fibrillation is associated with advanced age, obesity, cardiac dysfunction, chronic obstructive pulmonary disease, inflammation, and preoperative medications, with a strong correlation with old age and cardiac fibrosis.
WHAT THE STUDY ADDS
• Perioperative infusion of human natriuretic peptide (carperitide) reduces the occurrence of postoperative atrial fibrillation through a preventative effect.
• Factors such as an age >70 years, emergency surgery, preoperative aldosterone level >150 ng/mL, preoperative nonuse of angiotensin receptor blockers, preoperative use of calcium antagonists, postoperative nonuse of β blockers, postoperative nonuse of aldosterone blockers, and nonuse of carperitide were risk factors for postoperative atrial fibrillation. left ventricular dysfunction [EF<35%], BNP >300 pg/mL, ANP>100 pg/mL, ANP<20 pg/mL, angiotensin-II>20 pg/mL, aldosterone >150 pg/mL, high-sensitive C-reactive protein >3.0 mg/dL, and preoperative oral drug therapy) and perioperative factors (use of carperitide and postoperative oral drug therapy), the risk factors for POAF were investigated by the Cox proportional hazard model.
Statistical Analysis
Student t test was used to determine continuous variables with normal distribution, which was indicated by mean±SD, and the Mann-Whitney test with Bonferroni adjustment was used for nonparametric data, which was presented using box plot in Figures 1 to 3. For this reason, P<0.01 was considered as significant ( Figures 1-3) . The χ 2 test was used for the proportion. AF-free rate was estimated from Kaplan-Meier method. Cox proportional hazard model with stepwise selection process was used to calculate the P value(s), hazard ratio, and corresponding 95% confidence interval. A value of P<0.05 indicated statistical significance.
Results
Disposition of the Subjects
Initially, 700 patients were enrolled in this study, but 6 patients were switched to off-pump CABG, 13 patients underwent on-pump beating heart CABG, and 13 patients underwent concomitant operations. After these patients were excluded, 668 patients remained, including 335 in the carperitide group and 333 in the placebo group (Table 1) . No patient crossed over between the 2 groups, and all patients were analyzed as randomized.
Primary End Point
POAF occurred in 41 patients (12.2%) from the carperitide group versus 110 patients (32.7%) from the placebo group (P<0.0001; hazard ratio, 0.283; 95% confidence interval, 0.190-0.421).
POAF occurred after 2.98±1.39 days (median, 2.80 days; minimum, 0 day; maximum, 6 days) in the carperitide group versus 2.48±1.21 days (median, 2.44 days; minimum, 0 day; maximum, 7 days) in the placebo group (P=0.03; Figure 4 ).
Secondary End Points
Early Outcome
Death occurred within 30 days of surgery in 3 patients (0.9%) from the carperitide group and 7 patients (2.1%) from the placebo group, with no significant difference between the groups. Death occurred within 90 days in 5 patients (1.5%) from the carperitide group and 11 patients (3.3%) from the placebo group, again showing no significant difference.
Postoperative complications occurred in 21 carperitide patients (6.3%) and 47 placebo patients (14.1%), being less frequent, but its significant level was marginal in the carperitide group (P=0.047). Heart failure and cerebral infarction were also significantly less frequent in the carperitide group (P=0.04 and P=0.03, respectively). Cardiac failure occurred in 6 patients from the carperitide group and 15 patients from the placebo group, showing a significantly lower frequency in the carperitide group (P=0.03). Stroke occurred in 2 carperitide patients versus 9 placebo patients, and there were significantly fewer strokes in the carperitide group (P=0.03). POAF was associated with 2 deaths in the carperitide group and 8 deaths in the placebo group, showing no significant betweengroup difference (P=0.30). POAF occurred in 3 carperitide patients with heart failure and 10 placebo patients with heart failure, again showing was no significant between-group difference (P=0.66). POAF occurred in 1 carperitide patient with stroke and 3 placebo patients with stroke, and there was also no significant difference (P=1.00). Carperitide infusion was performed for 2.34±0.74 days in the carperitide group and physiological saline was infused for 2.78±1.81 days in the placebo group, with a significantly shorter infusion time in the carperitide group (P=0.002). This difference arose because the higher incidence of postoperative complications in the placebo group delayed initiation of oral medications. Both carperitide and saline were infused continuously and not discontinued for reasons such as hypotension in any patient ( Table 2) .
Renin Activity, Angiotensin-II, and Aldosterone
These preoperative parameters showed no significant differences between the 2 groups. Compared with the postoperative level, renin activity was significantly lower in the carperitide group on returning to intensive care unit (ICU), and angiotensin II was significantly lower in the carperitide group on returning to ICU and at 1 week postoperatively, whereas aldosterone was significantly reduced throughout the study (from returning to ICU and at 3 days and 1 week postoperatively; Figure 1 ).
BNP, ANP, and cGMP
There were no significant differences between the 2 groups on preoperative data. BNP was significantly reduced in the carperitide group throughout the postoperative period, whereas ANP increased rapidly to ≈10× the preoperative value. ANP was significantly higher in the carperitide group from returning to ICU until 3 days postoperatively, but there was no significant difference at 1 week. Similarly, cGMP was significantly elevated in the carperitide group until 3 days postoperatively, but not at 1 week ( Figure 2 ).
Creatine Kinase MB Isoenzyme and H-FABP
Creatine kinase MB isoenzyme was significantly reduced in the carperitide group from returning to ICU until 3 days postoperatively, whereas H-FABP was significantly lower at a returning to ICU (Figure 3 ).
High-Sensitivity C-Reactive Protein
High-sensitivity C-reactive protein showed no significant differences between the 2 groups at any time. Preoperative EF was 56.2±16.6% in the carperitide group versus 57.5±15.2% in the placebo group (P=0.26), whereas the EF at 2 weeks after surgery was 58.5±15.3% and 57.3±16.0%, respectively (P=0.36). Postoperative EF showed a significant increase in the carperitide group (P<0.0001), but no improvement was observed in the placebo group (P=0.35; Figure 3 ).
Factors Related to POAF
According to Cox proportional hazard model, significant predictors of POAF were ≥70 years, emergency surgery, preoperative aldosterone level >150 ng/mL, preoperative nonuse of angiotensin receptor antagonists, preoperative use of calcium antagonists, postoperative nonuse of β blockers, postoperative nonuse of aldosterone blockers, and nonuse of carperitide (Table 3 ).
Discussion
This study demonstrated that perioperative infusion of carperitide reduced POAF in patients undergoing CABG with CPB. The mechanisms involved may include (1) RAAS inhibition, (2) an anti-ischemic effect of carperitide, and (3) improvement of volume overload via a diuretic effect. Carperitide has been reported to inhibit the RAAS, and this was also observed in our previous study of patients undergoing cardiac surgery. Inhibition of RAAS activation by CPB may help to prevent postoperative cardiac and renal events, 8, 9 including POAF. An increase of angiotensin-II leads to Ca 2+ overload and triggers excitability that can lead to AF (electric remodeling). 12, 13 cAMP and the second messenger of carperitide (cGMP) have been reported to inhibit Ca 2+ overload, 14 and we previously demonstrated that carperitide inhibits myocardial Ca 2+ overload via cGMP in an animal model. 15 In the present study, carperitide ameliorated the postoperative increase of angiotensin-II and may also have inhibited Ca 2+ overload via cGMP and suppressed electric remodeling, thus preventing POAF. Aldosterone also influences heart failure and left ventricular remodeling, so inhibition of aldosterone by carperitide may have prevented postoperative heart failure and ventricular remodeling, resulting in a lower incidence of POAF.
Biomarkers of ischemia were significantly lower in the carperitide group. Carperitide has a cardioprotective effect and prevents ischemia-reperfusion injury. 16, 17 In a large-scale study of acute myocardial infarction, carperitide reduced the infarct area, improved left ventricular function, and reduced cardiac events. 18 We previously reported that carperitide improves volume overload and water retention by its strong diuretic effect. 19, 20 In the present study, BNP was significantly lower in the carperitide group after surgery and carperitide reduced left ventricular volume overload. In addition, the EF showed significant improvement at 2 weeks postoperatively in the carperitide group, but not in the placebo group. On the basis of these changes, we found that improvement of cardiac function and prevention of left ventricular remodeling by carperitide may have reduced POAF.
We also evaluated risk factors for POAF. A Cox proportional hazard model identified age >70 years, emergency surgery, preoperative aldosterone level >150 ng/mL, preoperative nonuse of angiotensin receptor antagonist, preoperative use of calcium antagonists, postoperative nonuse of β blockers, postoperative nonuse of aldosterone blockers, and nonuse of carperitide as risk factors.
Most previous studies have found that advanced age increases the risk of POAF. Elderly patients have more extensive myocardial fibrosis, which makes POAF more likely to occur. In our previous study, elderly patients and patients with high levels of fibrosis biomarkers had a higher risk of early postoperative POAF than patients with low ANP levels. 6 In the present study, although patients with low preoperative ANP levels had no risk of POAF, cardiac fibrosis and low endogenous ANP production may be compensated by carperitide, helping to prevent POAF.
Nonuse of angiotensin receptor antagonist, β-blockers (postoperatively), or aldosterone blockers (postoperatively) were other risk factors for POAF, as were high preoperative level of aldosterone. Although American College of Cardiology/American Heart Association/European Society of Cardiology guidelines recommend preoperative administration of β-blockers and amiodarone to prevent POAF, 7 no such guidelines have been developed in Japan and there have been no reports about angiotensin receptor antagonist or aldosterone blockers. It was reported that aldosterone blockers can prevent exacerbation of heart failure and cardiac fibrosis, [21] [22] [23] and Swedberg et al 24 recently demonstrated that the aldosterone blocker eplerenone decreased AF by 42% in patients with heart ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; and PAD, peripheral arterial disease. failure. They also reported that RAAS activation may contribute to atrial remodeling and fibrosis in patients with heart failure, thus serving as an important trigger of AF. 24 Furthermore, they suggested that aldosterone blockers may improve cardiac electric instability by preventing hypokalemia. 24 Moreover, aldosterone blockers have been shown to improve electric remodeling by reducing atrial structural remodeling and inhibiting fibrosis in animal studies. [25] [26] [27] Although the study of Swedberg et al 24 differed from our study with respect to the medication (eplerenone versus carperitide), number of subjects, and age range, both studies investigated renin-angiotensin system inhibitors.
Our results suggested that carperitide may prevent AF by influencing atrial remodeling because carperitide inhibited aldosterone and because carperitide is an atrial hormone. However, further examination of the relationship between carperitide and atrial remodeling is needed.
Because of RAAS activation by CPB and surgical inflammation, the incidence of AF is high after cardiac surgery. Our findings suggested that preoperative RAAS inhibition, perioperative administration of carperitide, and postoperative use of aldosterone blockers could control the RAAS and prevent POAF. In the present study, carperitide suppressed the RAAS, increased cGMP and ANP, suppressed fibrosis, improved left ventricular function, and reduced postoperative cardiac events including POAF. Accordingly, carperitide may be useful for preventing POAF and is also a potential upstream therapy for AF. Although carperitide is only available in Japan at present, a similar preparation (nesiritide) is available in Europe and the United States.
In the present study, carperitide had a preventive effect on POAF. Early death and postoperative complications were also less frequent in the carperitide group, along with a significantly lower incidence of both heart failure and stroke. However, there was no significant difference between the 2 groups with regard to the combined occurrence of POAF, death, heart failure, and stroke. Although we have no objection to reports that POAF influences the occurrence of stroke, the present study demonstrated that carperitide reduces the incidence of POAF, as well as postoperative death and complications, but did not demonstrate involvement of POAF with death and complications. This was probably because of the small number of patients with events in this study, so the association may be demonstrated by a larger investigation in the future.
Limitations
According to the American College of Cardiology/American Heart Association/European Society of Cardiology guidelines, administration of β-blockers is recommended to prevent AF after cardiac surgery. 7 Because guidelines have not been established in Japan, few patients received β-blockers in the present study. It was reported that β-blockers significantly decrease AF compared with placebo. Accordingly, whether administration of β-blockers combined with carperitide can reduce the incidence of AF should be investigated in the future. Because of statistical multiplicity, risk factors may be over estimated in the risk factor analysis.
In conclusion, this study provided the first evidence that perioperative infusion of carperitide can prevent POAF. ACEi indicates angiotensin-converting enzyme inhibitor; ANP, atrial natriuretic peptide; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; CI, confidence interval; COPD, chronic obstructive pulmonary disease; hs-CRP, high-sensitivity C-reactive protein; and PAD, peripheral arterial disease.
